SCHEDULE: Tang Capital Increases Stake in Aurinia Pharmaceuticals

Tang Capital Management and Kevin Tang have increased their beneficial ownership in Aurinia Pharmaceuticals to 10.0%.

Summary

• Tang Capital Management, LLC and associated entities, including CEO Kevin Tang, have increased their aggregate beneficial ownership of Aurinia Pharmaceuticals common shares to 13,044,106 shares.
• This ownership represents 10.0% of the total 129,991,655 common shares outstanding as of June 3, 2026.
• The reporting persons disclosed potential obligations to purchase an additional 1,000,000 shares via put option contracts expiring January 15, 2027, with a strike price of $15.00.
• Recent transactions between May 29, 2026, and June 2, 2026, involved the purchase of 814,606 shares at prices ranging from $14.97 to $15.50.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the CEO and associated investment firm are actively increasing their stake, signaling strong conviction in the company's future.

Positives

• Increased insider and major shareholder confidence through continued accumulation of shares.
• The reporting persons maintain a long-term investment perspective, reserving the right to acquire additional securities based on market conditions.

Negatives

• The reporting persons maintain the right to dispose of any or all of their securities at any time, which could create downward pressure on the stock price if they decide to exit.

Risks

• Potential future obligations to purchase 1,000,000 shares at $15.00 per share via put options.
• Market volatility and business prospects of the issuer could influence future investment decisions by the reporting persons.

Future Outlook

The reporting persons state that the acquisition was made for investment purposes and they may, from time to time, acquire additional shares or dispose of existing holdings depending on market conditions and the business prospects of the issuer.

Management Comments

• The reporting persons reserve the right to acquire additional shares or dispose of any or all of their securities at any time.

Industry Context

StockSavvy.ai notes that increased accumulation by a major shareholder who also serves as the CEO (Kevin Tang) is typically viewed as a strong signal of internal confidence in the company's pipeline and strategic direction within the competitive biopharmaceutical sector.

Comparison to Industry Standards

• The 10% ownership threshold is a significant milestone for institutional investors, often triggering increased scrutiny and influence over corporate governance.
• The use of put options to manage equity exposure is a standard hedging or accumulation strategy for sophisticated investment firms in the biotech space.

Legal Proceedings

• None reported.

Related Party Transactions

• The reporting persons are affiliated with the CEO of the issuer.

Stakeholder Impact

• Shareholders may view the increased ownership by the CEO and his firm as a stabilizing factor.
• Potential for increased volatility if the reporting persons decide to divest.

Next Steps

• Potential further open market transactions by the reporting persons.
• Monitoring of the January 15, 2027, put option expiration.

Key Dates

Recommendation

While the increased stake by the CEO is a positive signal, the stock is currently held by a major insider group with the flexibility to sell, suggesting a hold position until further operational milestones are achieved.

Keywords

Aurinia Pharmaceuticals, Tang Capital Management, Kevin Tang, Schedule 13D, Beneficial Ownership, Biotech Investment